One of the potential triggers for a shift towards a more mesenchymal phenotype is TGF-β, a regulatory cytokine playing multiple roles in cancer [38] and hyperactivation of the downstream signaling pathway of TGF-β is often observed in poor prognosis gliomas [39]. The gene discussed is TGFB1; the disease is glioma.